datopotamab deruxtecan 
GtoPdb Ligand ID: 13304
|
Synonyms: Dato-DXd | datopotamab deruxtecan-dlnk | Datroway® | DS-1062 | DS-1062a
datopotamab deruxtecan is an approved drug (FDA (2025))
Compound class:
Antibody
Comment: Datopotamab deruxtecan is an anti-TROP2 (TACSTD2) antibody drug conjugate (ADC). The cytotoxic payload is an exatecan-derived topoisomerase I inhibitor known as deruxtecan (DXd/MAAA1181a; PubChem CID 118305111). The ADC is highly stable in circulation and the DXd is only cleaved once inside cells where it induces DNA damage and apoptosis.
Overexpression of TROP2 is oncogenic and drives proliferation in cancer cells. |
| Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License